Immunology & Autoimmune Archives

Oct 22, 2026

Cancer-promoting protein helps engineered T cells fight tumors in mice

Activating the lipid-sensing transcription factor peroxisome proliferator-activated receptor delta (PPARδ) promoted cancer-cell growth but strengthened tumor-fighting immune cells when activated in a different cellular compartment, according to a study published October 14, 2026, in Nature Immunology. Researchers led by Paul Bunk, Ilgin Ergin and colleagues used genetically modified mouse tumors, immune-cell experiments and engineered human […]

Read the Full Bite →

Personalized neoantigen vaccine for ovarian cancer: what the phase 1 trial found

Cancer & Oncology

Oct 14, 2026

Personalized neoantigen vaccine for ovarian cancer: what the phase 1 trial found

A Nature Medicine phase 1 trial found that a personalized neoantigen vaccine generated tumor-specific immune responses in ovarian cancer, with biomarker evidence of biologic activity in 6 of 10 vaccinated patients.

Read the Full Bite →

Protective T cells may help slow atherosclerosis

Cardiovascular Health

Oct 11, 2026

Protective T cells may help slow atherosclerosis

A Circulation Research study found that protective CD8+ regulatory T cells restored Notch signaling in vascular smooth muscle cells and slowed atherosclerosis in mice.

Read the Full Bite →

Epstein-Barr virus reactivation precedes MS relapse: what the new study found

Clinical Research & Trials

Oct 10, 2026

Epstein-Barr virus reactivation precedes MS relapse: what the new study found

A longitudinal Nature Medicine study found EBV-associated B cell activity rising up to three months before multiple sclerosis relapse, suggesting viral reactivation may help prime attacks.

Read the Full Bite →

One dose of CAR-T cells shrinks solid tumors in preclinical study

Cancer & Oncology

Oct 6, 2026

One dose of CAR-T cells shrinks solid tumors in preclinical study

A new Nature Communications study identified MPZL1 as a potential CAR-T target in solid tumors and showed tumor regression in multiple preclinical models.

Read the Full Bite →

New study links MEK signaling to T cell exhaustion in cancer

Cancer & Oncology

Oct 5, 2026

New study links MEK signaling to T cell exhaustion in cancer

An Immunity study found that chronic MEK signaling increases the metabolic demand on cancer-fighting CD8 T cells, pushing them toward terminal exhaustion in experimental models.

Read the Full Bite →

Experimental multiple sclerosis drug reverses paralysis and vision loss in mice

Clinical Research & Trials

Sep 29, 2026

Experimental multiple sclerosis drug reverses paralysis and vision loss in mice

Kamuvudine-9 reversed paralysis and vision loss in a mouse model of multiple sclerosis. Here is what the study showed, and what remains unproven.

Read the Full Bite →

TYK2 and JAK1 explained: how immune signaling becomes a drug target

Cell & Molecular Biology

Sep 17, 2026

TYK2 and JAK1 explained: how immune signaling becomes a drug target

TYK2 and JAK1 help cytokines activate the JAK-STAT pathway. Here is how selective inhibition differs from broader JAK blockade and why it matters in autoimmune disease.

Read the Full Bite →

The virus behind infectious mononucleosis may trigger lupus and MS

Immunology & Autoimmune

Apr 30, 2025

The virus behind infectious mononucleosis may trigger lupus and MS

Stanford researchers add to evidence linking Epstein-Barr virus to autoimmune disease.

Read the Full Bite →